- 10:37 AM Kotak Institutional caution on telecom sector
- 10:33 AM Market volatility poses valuation problems: IRDA
- 10:33 AM Balrampur Chini can slip to Rs 111: M Thacker
- 10:28 AM Punjab, Haryana buck all-India rice decline trend
- 10:21 AM Hybrid cars may cost less as Govt mulls import dut...
- 10:18 AM Videocon up on oil discovery in Brazil’s BMC 30 bl...
- 10:11 AM Buy PTC India, says Mitesh Thacker
- 10:08 AM Divis Laboratories can test Rs 630-645: M Thacker
- 10:04 AM The real Alice in Wonderland's book up for auction
- 10:04 AM HCL Technologies signs $200mn deal; stk up



Botox, the flagship product of Allergan, Inc., has been approved for 20 unique indications in more than 50 countries- a fact that reaffirms its unique position as a pipeline of diverse and unique indications in a single product. An efficacious drug with a well-defined and extensively documented safety profile, Botox finds its applications today in both disabling diseases as well as lifestyle diseases affecting multitudes of people world wide.
Over the past decade, the uses of BOTOX® (botulinum toxin type A) have expanded as scientists and physicians continue to recognize its broad applicability. Originally used in the treatment of certain ophthalmic movement disorders, BOTOX® therapy is now widely accepted in many regions around the world as the gold standard for indications ranging from therapeutic neuromuscular disorders and related pain to cosmetic facial aesthetics.
Patrick T. Welch, Vice-President/ Managing Director - Asia Allergan Medical Aesthetics & Neurosciences said, “Allergan is committed to delivering innovations in the field of medical sciences and Botox today is looked upon to providing benefits to patients in 20 approved indications across the world. Our partnerships with physicians and our focus on continuous training and education programmes have helped create awareness amongst physicians and patients. We expect India to play a greater role with Botox in the coming years as we foresee growing awareness of our product in India and also an increase in usage of Botox in both cosmetic and therapeutic indications”.
Botox has been in existence in India for more than a decade, and is widely used today by diverse Specialities of physicians for both cosmetic and therapeutic purposes. Botox is one of the very few USD 1 Billion Pharma drugs in the world today. Numerous estimates suggest that Botox is set to continue with its strong growth over the coming few years.
Apart from its widespread cosmetic applications in treating hyperkinetic facial lines and glabellar lines (facial wrinkles), emerging areas of interest for clinicians in cosmetic treatments involve masseter treatments (facial slimming), intradermal treatment and face lift with Botox.
Having begun with initial support from celebrities, Botox now has widespread interest in Middle to Upper Middle Class Urban Indians as India quickly gets sensitized to the importance of looking better.
Sourced From: Blue Lotus Communications Pvt. Ltd
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Trading in MF units to start in 15 days: SEBI

- Experts see mkts at new highs, advise sectors

- 10 companies that MF managers love
- Corrections in '10 to be more aggressive, violent: JPMorgan

- Ganeshaspeaks: Market prediction for Nov 24
- Mahindra arm to bid for $3.5 bn defence deals
- Bollywood actress Shilpa Shetty marries Raj Kundra
- Kotak Institutional caution on telecom sector
Source: CNBC-TV18
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Balrampur Chini can slip to Rs 111: M Thacker
Source: CNBC-TV18
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line
- Hybrid cars may cost less as Govt mulls import duty cuts
Source: Business Line
- China`s Haitong Securities buys Hong Kong rival
Source: ft.com






















